Drug Profile
JNJ 61187165
Alternative Names: Ad26 RSV FA2; Ad26.RSV.FA2; JNJ-61187165-AAA; JNJ61187165Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Crucell Holland
- Developer Janssen Vaccines and Prevention B.V
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention, In volunteers) in USA (IM, Injection)
- 01 Sep 2016 Crucell Holland completes a phase I trial for Respiratory syncytial virus infections (In volunteers) in USA (NCT02561871)
- 01 Sep 2015 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention, In volunteers) in USA (IM)